ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026
The cost-effectiveness of implantable loop recorder detection of atrial fibrillation to prevent stroke in persons at high risk: An economic evaluation alongside a multicentre randomised controlled trial in Denmark (The LOOP Study).
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Closing Europe's Cardiovascular Implementation Gap: A Critical Review of the Safe Hearts Plan and the Cyprus Test Case.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsAtrial fibrillation (AF) is the most prevalent cardiac arrhythmia although often asymptomatic and undiagnosed. AF is associated with an increased stroke risk that can be mitigated with anticoagulation. Heart rhythm monitoring with implantable loop recorders (ILR) is efficacious in the detection of asymptomatic AF which allows for preventive measures. The study aimed to examine whether screening with ILR and anticoagulation upon AF detection was cost-effective to prevent stroke.
methodsThe study was designed as a cost-utility analysis alongside a randomised clinical trial. Its perspective was that of the health care and social care sector in Denmark. The time horizon was three years. Participants aged 70-90 years old with additional risk factors for AF and stroke were randomised to receive an ILR with anticoagulation upon detection of AF or to a control group. Quality-of-life (QoL) data were collected with the EQ-5D-5L instrument at baseline, 12, 24 and 36 months of follow-up. Danish tariffs were used to convert to health status measures to a QoL score to estimate quality-adjusted life-years (QALYs). Data on the participants' use of health care, social services and prescription drugs were found in Danish administrative registers. No participants had missing resource use data. Cost of the intervention with ILR was collected during the trial. Multiple imputation was performed to account for missing QoL data. Official tariffs, prices and agreements for health care, social services and medicines were used to estimate costs. All costs were calculated in 2022 prices. The costs and QALYs were discounted using an annual discount rate of 3.5%.
resultsAdjusting for 12 months of pre-baseline costs, the mean total discounted cost over the three years of follow up was 21,604 (95% CI 9,553 to 33,655) Danish kroner (DKK) higher in the ILR group than in the control group (1 DKK = 0.13 €). Adjusting for QoL at baseline, participants in the ILR group achieved an average of 2.2944 QALYs compared to 2.2807 QALYs in the control group. This is a difference of 0.0137 QALYs (95% CI -0.0091 to 0.0364). The probability of the ILR screening being cost-effective was less than 26% for defined threshold values for willingness to pay up to one million DKK per QALY gained.
conclusionsScreening for AF in 70-90-years-olds with an implantable loop recorder was not cost-effective within a time horizon of three years.
Identifiers
41779317What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.